Puma Biotech (PBYI) Tops Q2 EPS by 9c ; Offers Guidance

Puma Biotech (NASDAQ: PBYI) reported Q2 EPS of $0.10, $0.09 better than the analyst estimate of $0.01. Revenue for the quarter came in at $54.6 million versus the consensus estimate of $51.73 million.

GUIDANCE:

Puma Biotech sees Q3 2023 revenue of $51-53 million, versus the consensus of $51.73 million.

Puma Biotech sees FY2023 revenue of $205-210 million, versus the consensus of $231.4 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance
• Aebi Schmidt Holding AG (AEBI) Reports Q2 results; offers guidance